



**Abstract Accepted for Oral Presentation at EANM on DETECT Study  
Evaluating <sup>99m</sup>Tc-Maraciclatiside as a New Imaging Marker for Endometriosis**

London, UK, 9 July 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that an abstract on preliminary data from the DETECT “Detecting Endometriosis expressed integrins using technetium-99m” imaging study, has been accepted for oral presentation at the annual congress of the European Association of Nuclear Medicine (EANM) taking place from 18-23 October 2024 in Hamburg, Germany.

The study is investigating whether it is possible to visualise endometriosis, including superficial peritoneal disease, using <sup>99m</sup>Tc-maraciclatiside and SPECT-CT imaging. Superficial peritoneal endometriosis is the most common form of endometriosis accounting for approximately 80% of diagnoses and cannot be reliably detected using existing non-invasive imaging techniques such as ultrasound and MRI. Definitive diagnosis requires laparoscopy and there is an average delay to diagnosis of seven and a half years. This study aims to evaluate the potential of <sup>99m</sup>Tc-maraciclatiside in detecting endometriosis, and specifically superficial peritoneal endometriosis, which could have a significant impact on the lives of millions of women suffering with the disease.

The abstract titled “**Visualisation of Superficial Peritoneal Endometriosis with <sup>99m</sup>Tc-Maraciclatiside**” has been submitted by M Ghesani (Mount Sinai Hospital, New York, US); J Barnett (Serac Healthcare); T Gibbons (Oxford University, Oxford); D Burch (Serac Healthcare and John Radcliffe Hospital); S Cade and R Graham (Royal United Hospital, Bath); N Patel (John Radcliffe Hospital, Oxford); K Zondervan and C Becker (Oxford University, Oxford).

The study is ongoing and the presentation will include the latest findings and insights into the detection of disease subtypes.

**-ENDS-**

**For more information, please contact:**

David Hail, Chief Executive Officer

+44 (0)20 8948 0000  
[info@seraclifesciences.com](mailto:info@seraclifesciences.com)

Francetta Carr, Communications

+44 (0)7711 010820  
[francettacarr@seraclifesciences.com](mailto:francettacarr@seraclifesciences.com)

**Notes to Editors**

**About Serac Healthcare Ltd**

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

[www.serachealthcare.com](http://www.serachealthcare.com)

**Maraciclatiside is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.**

**About the DETECT study**

The study is jointly sponsored by Oxford Endometriosis CaRe Centre and the Nuffield Department of Women's and Reproductive Health, Oxford University, and funded by Serac Healthcare Ltd who are providing the experimental imaging marker <sup>99m</sup>Tc-maraciclalide. Further details are available on ClinicalTrials.gov [here](#).

**About EANM:** <https://eanm24.eanm.org/>